Jump Financial LLC Has $1.27 Million Position in Kura Oncology, Inc. $KURA

Key Points

• Jump Financial LLC reduced its stake in Kura Oncology by 19.7%, now holding approximately 0.22% of the company worth $1.27 million.
• Kura Oncology's stock experienced a 2.7% increase in trading, opening at $8.07, with a 12-month range from $5.41 to $21.57.
• Analyst recommendations vary, with a consensus rating of "Moderate Buy" and an average price target of $24.10 for Kura Oncology shares.

Jump Financial LLC lessened its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 19.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 192,711 shares of the company's stock after selling 47,222 shares during the quarter. Jump Financial LLC owned approximately 0.22% of Kura Oncology worth $1,272,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in Kura Oncology by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock valued at $32,658,000 after buying an additional 129,337 shares during the last quarter. RA Capital Management L.P. bought a new position in Kura Oncology in the 4th quarter valued at approximately $38,769,000. Millennium Management LLC raised its holdings in Kura Oncology by 180.1% in the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after buying an additional 1,521,954 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Kura Oncology by 35.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock valued at $12,419,000 after buying an additional 372,196 shares during the last quarter. Finally, Prosight Management LP raised its holdings in Kura Oncology by 87.9% in the 4th quarter. Prosight Management LP now owns 1,325,000 shares of the company's stock valued at $11,541,000 after buying an additional 619,891 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have issued reports on KURA shares. Wall Street Zen upgraded shares of Kura Oncology from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. Mizuho lowered their price target on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, May 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 26th. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. Finally, JMP Securities lowered their price target on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Kura Oncology has a consensus rating of "Moderate Buy" and a consensus price target of $24.10.

Kura Oncology Trading Down 2.1%

Shares of KURA stock traded down $0.17 during trading hours on Friday, hitting $7.90. 1,676,056 shares of the company were exchanged, compared to its average volume of 1,967,537. The firm has a market cap of $685.72 million, a P/E ratio of -3.50 and a beta of 0.19. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $21.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The company has a 50 day simple moving average of $6.43 and a two-hundred day simple moving average of $6.56.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million. Equities analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.